Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

157.68USD
11:35am EDT
Change (% chg)

$1.93 (+1.24%)
Prev Close
$155.75
Open
$156.16
Day's High
$158.47
Day's Low
$156.16
Volume
23,524
Avg. Vol
143,131
52-wk High
$208.78
52-wk Low
$71.45

Summary

Name Age Since Current Position

Joshua Bilenker

46 2013 President, Chief Executive Officer, Director

Jennifer Burstein

46 2018 Senior Vice President - Finance

Jacob Van Naarden

33 2015 Chief Business Officer

Keith Flaherty

46 2013 Director

Lori Kunkel

59 2014 Director

Steven Elms

53 2013 Independent Director

Alan Fuhrman

60 2015 Independent Director

Steven Harr

47 2016 Independent Director

Timothy Mayleben

57 2015 Independent Director

Avraham Naider

45 2013 Independent Director

Biographies

Name Description

Joshua Bilenker

Dr. Joshua H. Bilenker (Josh), M.D. is President, Chief Executive Officer, Director of Loxo Oncology Inc. Since November 2013, Dr. Bilenker has served as President and Chief Executive Officer since June 2013 and as a member of our board of directors since June 2013. Since November 2013, Dr. Bilenker has served as an Operating Partner at Aisling Capital LLC, or Aisling Capital, a private equity firm, where he was a Partner from January 2012 to October 2013 and previously served as a Principal from October 2008 to December 2011 and an Associate from April 2006 to September 2008. Dr. Bilenker is on the board of directors of T2 Biosystems and Viewray Inc. He also serves on the nonprofit boards of BioEnterprise and The NCCN Foundation. From 2004 to 2006, Dr. Bilenker served as a Medical Officer at the FDA in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree in English from Princeton University.

Jennifer Burstein

Ms. Jennifer Burstein, CPA is Senior Vice President - Finance of Loxo Oncology, Inc. Prior to Loxo, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015, where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance. Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.

Jacob Van Naarden

Mr. Jacob Van S. Naarden is the Chief Business Officer of the Loxo Oncology Inc. prior to that he served as our Vice President of Corporate Development and Strategy, since May 2014. Prior to joining Loxo Oncology, Mr. Van Naarden was an analyst at HealthCor Management from June 2013 to May 2014. From August 2008 to June 2013, Mr. Van Naarden worked at Aisling Capital, initially as an analyst and later as an associate. Mr. Van Naarden started his career at Goldman Sachs, where he worked from July 2006 to June 2008. Mr. Van Naarden received his A.B. in Molecular Biology from Princeton University.

Keith Flaherty

Dr. Keith T. Flaherty, M.D. is Director of Loxo Oncology Inc. He has served as a member of our board of directors since September 2013. He is Director of the Henri and Belinda Termeer Center for Targeted Therapy and Clinical Research, Massachusetts General Hospital Cancer Center, and is an Associate Professor of Medicine at Harvard Medical School. He has worked as a physician at Massachusetts General Hospital since 2009. Dr. Flaherty serves on the board of directors of Clovis Oncology, Inc., a biopharmaceutical company. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certifications in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree in Neurobiology from Yale University.

Lori Kunkel

Dr. Lori A. Kunkel, M.D. is Director of Loxo Oncology, Inc. Dr. Kunkel has served on the board of directors since October 2014. She previously served as Acting Chief Medical Officer for Loxo Oncology. Prior to Loxo, Dr. Kunkel served as Chief Medical Officer at Pharmacyclics, a biopharmaceutical company, from November 2011 until August 2013 where she was responsible for building and leading an integrated clinical development and medical affairs organization highlighted by the approval of IMBRUVICA. From February 2009 until joining Pharmacyclics she served as a clinical advisor to Syndax, a biopharmaceutical company. Previously she served as Chief Medical Officer at Proteolix, a biotechnology company acquired by Onyx, where she oversaw the clinical development of KYPROLIS. She has held senior roles at ACT Therapeutics, Xencor, and Genitope. Dr. Kunkel trained in internal medicine at Baylor College of Medicine, and in hematology-oncology at USC and UCLA, earning board certification in these specialties. Dr. Kunkel received her M.D. from University of Southern California and her B.A. degree from University of California San Diego.

Steven Elms

Mr. Steven A. Elms, (Steve) is Independent Director of Loxo Oncology Inc. He has served as a member of our board of directors since July 2013. He currently serves as a Managing Partner of Aisling Capital LLC, a private equity firm. He joined Aisling Capital LLC in 2000 from the life sciences investment banking group of Chase H&Q (formerly Hambrecht and Quist Group Inc.) where he was a principal. Mr. Elms serves on the board of directors of ADMA Biologics, Inc. Previously, Mr. Elms served on the board of directors of Ambit Biosciences Corp. from 2001 to 2014, MAP Pharmaceuticals, Inc. from 2004 to 2011 and has served on the boards of directors of a number of private companies. Mr. Elms received his B.A. in Human Biology from Stanford University and his M.B.A. from the Kellogg Graduate School of Management at Northwestern University. We believe that Mr. Elms should serve on our board of directors due to his extensive financial services background and experience in the pharmaceutical and healthcare industries.

Alan Fuhrman

Mr. Alan Fuhrman is Independent Director of the Loxo Oncology Inc. Mr. Fuhrman has served as a member of our board of directors since January 2015. He previously served as the chief financial officer of Ambit Biosciences from October 2010 until its recent sale to Daiichi Sankyo for up to $410 million. Prior to this role, he served as chief financial officer of Naviscan, Inc., a privately-held medical imaging company from November 2008 until September 2010, and as chief financial officer of Sonus Pharmaceuticals from September 2004 until August 2008. Earlier in Mr. Fuhrman’s career he practiced as a CPA with Coopers and Lybrand. Mr. Fuhrman received B.S. degrees in both business administration and agricultural economics from Montana State University.

Steven Harr

Dr. Steven D. Harr, M.D. is Independent Director of the Company. From April 2014 to March 2018, Dr. Harr served as Chief Financial Officer and Head of Corporate Development of Juno Therapeutics. Previously, he served in various roles at Morgan Stanley, including as Managing Director and Head of Global Biotech Investment Banking from 2010 to 2014. Prior to that, Dr. Harr was Morgan Stanley’s lead biotech research analyst and co-head of Global Healthcare Research. Dr. Harr also serves on the board of directors of JW Therapeutics. Dr. Harr received his B.A. in Economics from the College of the Holy Cross, his M.D. from Johns Hopkins School of Medicine, and was an internal medicine resident at the University of California, San Francisco. We believe Dr. Harr should serve on our board of directors due to his financial expertise and knowledge of the biotechnology and healthcare industries.

Timothy Mayleben

Mr. Timothy M. Mayleben, (Tim) is Independent Director of the Company. Mr. Mayleben currently serves as president and chief executive officer of Esperion Therapeutics and has been a member of the board of directors of Esperion since 2010. Prior to joining Esperion, Mr. Mayleben was president, CEO and a director of Aastrom Biosciences. Previously, he was president, chief operating officer and a director of NightHawk Radiology Holdings. Prior to joining Nighthawk, Tim was chief operating officer of the original Esperion until its acquisition by Pfizer in 2004 for $1.3 billion. Mr. Mayleben is a board member of several life science companies, including Kaléo Pharma, Lycera Corporation, and Marinus Pharmaceuticals and an advisor to the Wolverine Venture Fund. Mr. Mayleben earned an MBA with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business. We believe that Mr. Mayleben should serve on our board of directors due to his public company experience and understanding of the pharmaceutical industry.

Avraham Naider

Mr. Avraham Z. Naider, (Avi) is Independent Director of Loxo Oncology. Inc. Mr. Naider has served as a member of our board of directors since September 2013. Mr. Naider is Chairman and CEO of ACES Risk Management Corp., a software company, a position he has held since January 2008. Mr. Naider is also a private investor and consultant to various companies. Prior to joining ACES, Mr. Naider founded an internet advertising software company, worked in private equity and was an associate at the Boston Consulting Group. Mr. Naider received his A.B. in the Woodrow Wilson School of Public and International Affairs from Princeton University.

Basic Compensation

Name Fiscal Year Total

Joshua Bilenker

3,914,460

Jennifer Burstein

786,152

Jacob Van Naarden

1,558,680

Keith Flaherty

659,903

Lori Kunkel

593,903

Steven Elms

625,403

Alan Fuhrman

613,903

Steven Harr

600,255

Timothy Mayleben

606,873

Avraham Naider

601,403
As Of  30 Dec 2017

Options Compensation